Apyx Medical Corp

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

APYX$2.94+0.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Equity for the

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands)

Common Stock · Additional Paid-In Capital · Accumulated Deficit · Non-controlling Interest · Total Equity
Shares · Par Value
Balance at December 31, 2022	34,598	$35	$73,282	$(35,735)	$211		$37,793
Stock based compensation	—	—	1,367	—	—	1,367
Proceeds received from issuance of warrants	—	—	586	—	—	586
Net loss	—	—	—	(3,483)	(49)	(3,532)
Balance at March 31, 2023	34,598	$35	$75,235	$(39,218)	$162		$36,214
Shares issued on stock options exercised for cash	25	—	56	—	—	56
Stock based compensation	—	—	1,482	—	—	1,482
Shares issued on net settlement of stock options	6	—	—	—	—	—
Net loss	—	—	—	(994)	(25)	(1,019)
Balance at June 30, 2023	34,629	$35	$76,773	$(40,212)	$137		$36,733
Common Stock · Additional Paid-In Capital · Accumulated Deficit · Non-controlling Interest · Total
Shares · Par Value
Balance at December 31, 2023	34,644	$35	$81,114	$(54,448)	$221		$26,922
Stock based compensation	—	—	1,128	—	—	1,128
Net loss	—	—	—	(7,576)	(14)	(7,590)
Balance at March 31, 2024	34,644	$35	$82,242	$(62,024)	$207		$20,460
Stock based compensation	—	—	1,050	—	—	1,050
Net loss	—	—	—	(6,556)	(30)	(6,586)
Balance at June 30, 2024	34,644	$35	$83,292	$(68,580)	$177		$14,924

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Six Months Ended June 30,
	2024	2023
Cash flows from operating activities
Net loss	$(14,176)	$(4,551)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	313	354
Provision for inventory obsolescence	60	178
Loss (gain) on disposal of property and equipment	20	(2,692)
Stock based compensation	2,178	2,849
Allowance for credit losses	45	55
Non-cash lease expense	62	22
Non-cash interest expense	443	209
Changes in operating assets and liabilities:
Trade receivables	1,187	(1,441)
Prepaid expenses and other assets	666	(57)
Income tax receivables	—	(207)
Inventories	547	534
Accounts payable	(345)	(26)
Accrued and other liabilities	(1,670)	(1,960)
Net cash used in operating activities	(10,670)	(6,733)
Cash flows from investing activities
Purchases of property and equipment	(324)	(266)
Proceeds from sale of property and equipment	—	7,267
Net cash (used in) provided by investing activities	(324)	7,001
Cash flows from financing activities
Proceeds from stock option exercises	—	56
Proceeds from long-term debt	—	9,289
Payment of debt issuance costs	—	(1,754)
Proceeds from debt allocated to warrants	—	586
Repayment of finance lease liabilities	(10)	(19)
Net cash (used in) provided by financing activities	(10)	8,158
Effect of exchange rates on cash	30	(139)
Net change in cash and cash equivalents	(10,974)	8,287
Cash and cash equivalents, beginning of period	43,652	10,192
Cash and cash equivalents, end of period	$32,678	$18,479
Cash paid for:
Interest	$2,371	$431
Income taxes	$180	$227
Non cash activities:
Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease	$—	$4,917

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.